 HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 07, 2021 GLOBE NEWSWIRE -- HUTCHMED China Limited HUTCHMED NasdaqAIM: HCM, HKEX: 13 today announces that new analyses and updates on the ongoing studies of amdizalisib PI3Kδ inhibitor HMPL-689, savolitinib ORPATHYS in China and fruquintinib ELUNATE in China will be presented at the upcoming 2021 European Society for Medical Oncology ESMO Virtual Congress taking place on September 16-21, 2021. 